GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Current Ratio

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Current Ratio : 0.19 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. IPI Legacy Liquidation Co's current ratio for the quarter that ended in Sep. 2023 was 0.19.

IPI Legacy Liquidation Co has a current ratio of 0.19. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If IPI Legacy Liquidation Co has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.

The historical rank and industry rank for IPI Legacy Liquidation Co's Current Ratio or its related term are showing as below:

IMPLQ' s Current Ratio Range Over the Past 10 Years
Min: 0.19   Med: 4.75   Max: 7.28
Current: 0.19

During the past 4 years, IPI Legacy Liquidation Co's highest Current Ratio was 7.28. The lowest was 0.19. And the median was 4.75.

IMPLQ's Current Ratio is ranked worse than
94.67% of 1557 companies
in the Biotechnology industry
Industry Median: 3.73 vs IMPLQ: 0.19

IPI Legacy Liquidation Co Current Ratio Historical Data

The historical data trend for IPI Legacy Liquidation Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Current Ratio Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Current Ratio
4.75 0.78 5.93 3.60

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.97 3.60 2.33 0.27 0.19

Competitive Comparison of IPI Legacy Liquidation Co's Current Ratio

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Current Ratio falls into.



IPI Legacy Liquidation Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

IPI Legacy Liquidation Co's Current Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Current Ratio (A: Dec. 2022 )=Total Current Assets (A: Dec. 2022 )/Total Current Liabilities (A: Dec. 2022 )
=79.809/22.163
=3.60

IPI Legacy Liquidation Co's Current Ratio for the quarter that ended in Sep. 2023 is calculated as

Current Ratio (Q: Sep. 2023 )=Total Current Assets (Q: Sep. 2023 )/Total Current Liabilities (Q: Sep. 2023 )
=23.427/124.743
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IPI Legacy Liquidation Co  (OTCPK:IMPLQ) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


IPI Legacy Liquidation Co Current Ratio Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Headlines